Next Article in Journal
Biotinylated Chlorin and Its Zinc and Indium Complexes: Synthesis and In Vitro Biological Evaluation for Photodynamic Therapy
Next Article in Special Issue
Pathogenesis and Inhibition of Flaviviruses from a Carbohydrate Perspective
Previous Article in Journal
Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
Previous Article in Special Issue
Systematic Analysis of Pharmaceutical Preparations of Chondroitin Sulfate Combined with Glucosamine
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 10
Issue 2
10.3390/ph10020042
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Glycosaminoglycan Binding and Non-Endocytic Membrane Translocation of Cell-Permeable Octaarginine Monitored by Real-Time In-Cell NMR Spectroscopy

by
Yuki Takechi-Haraya
1,†,
Kenzo Aki
1,
Yumi Tohyama
1,
Yuichi Harano
1,
Toru Kawakami
2,
Hiroyuki Saito
3 and
Emiko Okamura
1,*
1
Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, 7-2-1 Kamiohno, Himeji 670-8524, Japan
2
Institute for Protein Research, Osaka University, 3-2 Yamadaoka, Suita, Osaka 565-0871, Japan
3
Department of Biophysical Chemistry, Kyoto Pharmaceutical University, 5 Nakauchi-cho, Misasagi, Yamashina-ku, Kyoto 607-8414, Japan
*
Author to whom correspondence should be addressed.
†
Present address: Division of Drugs, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
Pharmaceuticals 2017, 10(2), 42; https://doi.org/10.3390/ph10020042
Submission received: 16 February 2017 / Revised: 27 March 2017 / Accepted: 12 April 2017 / Published: 15 April 2017
(This article belongs to the Special Issue Glycosaminoglycans and Proteoglycans)
Browse Figures
Versions Notes

Abstract

:
Glycosaminoglycans (GAGs), which are covalently-linked membrane proteins at the cell surface have recently been suggested to involve in not only endocytic cellular uptake but also non-endocytic direct cell membrane translocation of arginine-rich cell-penetrating peptides (CPPs). However, in-situ comprehensive observation and the quantitative analysis of the direct membrane translocation processes are challenging, and the mechanism therefore remains still unresolved. In this work, real-time in-cell NMR spectroscopy was applied to investigate the direct membrane translocation of octaarginine (R8) into living cells. By introducing 4-trifluoromethyl-l-phenylalanine to the N terminus of R8, the non-endocytic membrane translocation of 19F-labeled R8 (19F-R8) into a human myeloid leukemia cell line was observed at 4 °C with a time resolution in the order of minutes. 19F NMR successfully detected real-time R8 translocation: the binding to anionic GAGs at the cell surface, followed by the penetration into the cell membrane, and the entry into cytosol across the membrane. The NMR concentration analysis enabled quantification of how much of R8 was staying in the respective translocation processes with time in situ. Taken together, our in-cell NMR results provide the physicochemical rationale for spontaneous penetration of CPPs in cell membranes.

1. Introduction

Drug delivery using cell-penetrating peptides (CPPs) is one of the most powerful strategies to resolve the poor cell membrane permeability of new bioactive molecules such as oligonucleotides, plasmids, peptides and proteins for therapeutic pharmaceuticals [1]. Arginine- or lysine-rich CPPs can deliver such cargoes into cells in vitro and in vivo [2,3,4]. Although the endocytic pathway has been thought to be significant [5], more than 90% of the delivered cargo become biologically inactive because of lysosomal degradation [6]. CPPs also traverse cell membrane via the non-endocytic pathway at high concentrations, > ~5–10 μM [7,8]. This process is often named as direct membrane translocation or transduction. The mechanism is essentially a physicochemical, energy-independent process in which no receptors are required [9]. Although the direct membrane translocation is an alternative to endocytosis in order to avoid the lysosomal degradation, how cationic CPPs traverse hydrophobic cell membranes is still controversial [10].
As a first step of membrane translocation, cationic CPPs are thought to interact with negatively charged, sulfated glycosaminoglycans (GAGs) such as heparan sulfate and chondroitin sulfate which are covalently linked to membrane proteins at the cell surface [11,12,13,14]. The GAG clustering is induced via the electrostatic interaction with CPP, followed by the actin rearrangement that leads to endocytosis [15,16]. On the other hand, the GAG clustering also triggers the direct membrane translocation of CPPs at high CPP concentrations (> 5 μM) [17]. Although CPPs bind to and translocate into GAG-deficient cells and enzymatically GAG-removed cells [12,13,18,19], we have recently reported that the efficiency of the direct membrane translocation of arginine-rich CPPs is correlated with the favorable enthalpy of binding to heparin, of which the binding could be derived from formation of multidentate hydrogen bonding of the arginine residue with sulfate group of heparin [20]. In addition, the previous study has demonstrated that the direct membrane translocation of arginine-rich peptides including octaarginine (R8) is markedly reduced by the chlorate treatment, which prevents sulfation of both heparan sulfate and chondroitin sulfate chains [20]. Based on these facts, the non-endocytic membrane translocation of arginine-rich CPPs would follow three distinct steps: (1) binding to sulfated GAGs at the cell surface; (2) translocation into cells over potential barrier of the hydrophobic cell membrane; and (3) diffusion through the cytosol. However, in situ comprehensive observation and quantitative analysis of the non-endocytic membrane translocation processes are challenging, and the mechanism therefore remains still unsolved [10].
So far, almost all membrane translocation studies have relied upon the fluorescent labeling of CPPs or delivered cargo. Despite the high sensitivity, fluorophores are likely to strengthen the interaction of CPPs with lipid membrane [16,21], induce photodamage of lipid bilayer membranes [22], facilitate the uptake into the cell [23], modify the cellular distribution of the CPP [24,25], and change the structural flexibility and conformation of CPP [26]. Recently, an innovative MALDI TOF-MS quantification was reported by using biotin–avidin interaction [27,28,29]. Although the biotinylated CPP at as low as a femtomole scale has been quantified after the incubation with cells, the method has not been able to catch the real-time processes of CPP’s translocation into cells. Recently- developed real-time NMR spectroscopy [30] is a potential technique for the observation of biologically-relevant functions in a natural manner.
In this work, the real-time solution NMR method is applied to natural living cells to investigate the mechanism for non-endocytic membrane translocation of cell-permeable octaarginine (R8). By introducing 4-trifluoromethyl-l-phenylalanine (4CF3-Phe) to the N terminus of R8, the direct membrane translocation of 19F-labeled R8 (19F-R8) into a human myeloid leukemia cell line (HL60) is observed by 19F NMR with a time resolution at a minute scale. 19F NMR is advantageous because it is sensitive and no background is present in the cell. The small size, large chemical shift range, and 100% natural isotope abundance of the 19F nucleus have made the use of 19F-labeled peptides and proteins an attractive method for biologically-relevant NMR studies [31,32]. Labeling of R8 with 4CF3-Phe is found to be an effective method to detect peptide uptake to cells with minimal perturbation [23]. In addition, 19F NMR spectroscopy enables us to make a quantitative (concentration) analysis relevant to the molecular dynamics of biological interest without perturbing the system [33,34,35,36]. Here we observe the direct membrane translocation of 19F-R8 at 4 °C, the temperature low enough to assure no endocytic pathway of the cellular uptake [37]. The method can detect the successive processes of 19F-R8 translocation: (1) 19F-R8 binds to GAG at the cell surface; (2) penetrates into the cell membrane; and (3) finally enters the cytosol through the membrane. In addition, 19F NMR concentration analysis quantifies how much of 19F-R8 is in the processes (1)–(3) with time. The information is valuable because the analysis of time-resolved drug transport has been limited to the uptake of a small drug-like ion via the Escherichia coli membrane by using second harmonic generation [38]. We also confirm the 19F-R8 uptake to the cytosol of HL60 cells using cell fractionation after equilibrium was attained in the real-time NMR measurement. Finally, the most plausible mechanism of the non-endocytic 19F-R8 entry into the cell is discussed.

2. Results

2.1. Real-Time In-Cell 19F NMR Spectra

To capture the real-time process of non-endocytic membrane translocation of 19F-R8, the solution 19F NMR measurement was performed at 4 °C with a time resolution at a minute scale. In order to confirm no contribution of endocytosis at 4 °C, the comparative measurement was also performed at 37 °C. Figure 1a,b shows the real-time 19F NMR spectra of 19F-R8 before (0 min) and after the addition to HL60 cells at 4 and 37 °C, respectively. At 4 °C (Figure 1a), a signal is observed at −62.20 ppm, that is assignable to the F nuclei of 4CF3-Phe at the N terminus of R8. The assignment is confirmed by Figure S1 where signals of 4CF3-Phe at −62 ppm and trifluoroacetate (TFA) counter anions at −76 ppm are present with an intensity ratio (4CF3-Phe/TFA) of 1:8. At 37 °C, the 19F-R8 signal was shifted to −61.66 ppm (Figure 1b). In addition, a new peak was observed at −61.84 ppm after 10 min, and gradually increased with time. The increase of the peak at −61.84 ppm was coupled with a gradual decrease in the original signal at −61.66 ppm. The appearance of a new peak with the disappearance of the original one is due to the presence of cells because such kind of signal changes is not observed in the absence of cells at 37 °C (spectra not shown). Thus the new peak observed at 37 °C is thought to be the result of endocytosis involving peptide degradation [39]. Since such kind of spectral change is not found in Figure 1a, it is reasonable to consider that no endocytosis occurs at 4 °C. The absence of endocytosis at 4 °C is also consistent with the previous results of cell-penetrating peptides [8,9].
Figure 2a shows an expansion of the real-time 19F NMR spectra of 19F-R8 at 4 °C in PBS (0 min) and 4, 6, 8, 10, 12, 14 and 16 min after the addition to HL60 cells. In comparison to the spectrum in PBS (0 min), the signal is broadened due to the appearance of new component (red arrow) at the low magnetic field within the first 4 min after 19F-R8 was incubated with cells. We call it state I. After 6 min, the signal comes back to the high field and becomes sharper (state II). This is because the low field component gradually decreases in intensity during the period from 4 to 6 min. After 8 min, however, the peak top of the signal slightly moves to the lower field again (state III). No further change is observed in the 19F-R8 signal after 10 min and later, indicating that the system reaches an equilibrium state.
As mentioned above, the time-dependent spectral changes in Figure 2a imply that at least three different states I-III of 19F-R8 are present after the addition to HL60 cells. We repeated in-cell NMR measurement three times, and confirmed such states every time of the measurement. To distinguish states I, II, and III clearly, it is convenient to see the difference spectrum. The difference spectrum analysis is useful in the present study because the integral intensity of 19F-R8 is conserved all the time (see Supplementary Materials Figure S2); notice that no degradation of 19F-R8 is induced at 4 °C by the presence of HL60 cells. By subtracting the spectrum of 19F-R8 in PBS (0 min) from each spectrum after 4, 6, 8, 10, 12, 14 and 16 min with cells, we can obtain the difference spectra as illustrated in Figure 2b.
The time course of the difference spectra shows that probably three components of 19F-R8 are present after 19F-R8 is added to HL cells, in addition to the free component at −62.20 ppm. At first, two peaks are observed at −62.19 and −62.21 ppm after 4 min. These peaks can be assigned to 19F-R8 bound to GAG (GAG in Figure 2b) and 19F-R8 that interacts with the cell membrane (Membrane). Details of the assignment will be described later. Then, the third peak appears at −62.205 ppm after 6 min and increases in intensity after 8 min; see asterisk in Figure 2b. This peak can be assigned to 19F-R8 in cytosol (Cytosol) after passing through the membrane.
It is noted that the peak assignments are reasonable in view of the following results of 19F NMR and isothermal titration calorimetry (ITC). The first is that the NMR chemical shift of 19F-R8 moves toward the low magnetic field as compared to 19F-R8 in PBS when 19F-R8 is mixed with heparin; see Figure 3a. Because heparin is frequently used as a model of GAG [40,41,42,43,44,45], it is reasonable to assign the broad component at −62.19 ppm to 19F-R8 that is bound to GAG. According to the fact that NMR signal intensity is reduced by slower rotational movement of a molecule related to short transverse relaxation time, it should be noted that the rotational dynamics of 19F-R8 are restricted due to the tighter binding to heparin, as previously discussed [20]. The high affinity of R8 for heparin is confirmed by the ITC result in Figure 4 that leads the association constant 1.3 × 108 M−1, and the binding free energy, −10.9 kcal/mol at 25 °C, as listed in Table 1. The binding nature of R8 is largely derived from the electrostatic interaction between arginine residues and anionic sulfate/carboxyl groups of heparin [20]. The binding stoichiometry (molar ratio of peptide/heparin = ~11) corresponds approximately to the ratio for the charge neutralization (the heparin molecule used possesses an average of 80 anionic charges, whereas there are 8 cationic charges of octaarginine). The assignment also corresponds well with the previous consensus that R8 at first comes contact with GAG at the cell surface by the electrostatic interaction [46]. The second is that the 19F NMR signal moves to a high magnetic field where 19F-R8 interacts with cell membrane, in contrast to the electrostatic 19F-R8 binding to GAG. As illustrated in Figure 3b, it is confirmed that the 19F-R8 signal shifts to a high field after the binding to large unilamellar vesicle (LUV) composed of egg phosphatidylcholine (EPC) and egg phosphatidylglycerol (EPG) as model cell membrane. The result is consistent with the observation that the chemical shift of the 19F NMR signal moves to the higher magnetic field when 19F molecules are in a hydrophobic environment [23,47,48]. Similar to the case of heparin binding, the NMR signal intensity of 19F-R8 is also reduced due to the binding to EPC/EPG LUV. The presence of energetically-favorable interaction between R8 and EPC-EPG membrane is also demonstrated by the ITC result in Figure 5 that gives the association constant, 1.5 × 106 M−1 and the binding free energy, −8.4 kcal/mol at 25 °C (Table 1). The binding stoichiometry (molar ratio of lipid/peptide = ~100) is close to the ratio for charge neutralization, that is, the molar ratio of EPG in the outer leaflet of the LUVs to the positively charged residues of octaarginine is ~1. Thus we can consider that the most plausible assignment of the peak at −62.21 ppm is 19F-R8 in the cell membrane. Finally, it is reasonable to assign the third peak at −62.205 ppm (*) as 19F-R8 in cytosol, because the peak comes back to the lower magnetic field due to rather hydrophilic cytosol environment as compared to the cell membrane. The presence of 19F-R8 in cytosol is also confirmed by cell fractionation, the details of which will be described later.
Based on the assignment of the 19F NMR spectra in Figure 2, here we propose a hypothesis about the most probable mechanism of non-endocytic membrane translocation of 19F-R8 to HL60 cells as the following: (1) 19F-R8 first binds to GAG (state I); (2) penetrates into cell membrane (state II); and (3) finally enters the cytosol (state III). In Figure 2b, the three components of 19F-R8 bound to GAG, 19F-R8 in membrane, and in cytosol are demonstrated by the dotted lines in black, green, and red, respectively, together with the free component (Free) in blue. It is found that the signal of 19F-R8 bound to GAG and that in membrane already appear 4 min after the addition to cells. The GAG signal quickly decays with time and almost disappears after 6 min. Meanwhile, the membrane signal decays slowly as compared to GAG. Then, the signal in cytosol (Cytosol) is identified at 6 min, a few minutes after GAG and Membrane peaks are observed. The Cytosol signal is gradually increased with time and almost unchanged after 10 min, to confirm the equilibrium state of the translocation of 19F-R8 to HL cells. The observed minute-ordered direct membrane translocation of 19F-labeled octaarginine is consistent with our previous study that has confirmed the cell penetration of fluorescently-labeled octaarginine within at least 30 min [20]. There have also been reported that the fluorescently-labeled R8 and biotin-labeled nonaarginine penetrate into cells after about 5 min at 4 °C [7,8].
To verify the reliability of the analysis, a membrane-impermeable human lens αA-crystallin fragment, called 19F-T6 (TV-(4CF3-Phe)-DSGISEVR), was added to HL60 cells, and the spectra were compared. As 19F-T6 includes two acidic and one cationic amino acids, the negative net charge is held under physiological conditions. The interaction between 19F-T6 and negatively charged GAG is, therefore, not expected at the cell surface. In fact, as shown in Figure 2c,d, no changes were found in the 19F NMR spectrum nor the difference spectrum of 19F-T6 even 16 min after the addition to cells. The situation is a sharp contrast to 19F-R8 where the equilibrium has been already attained for the membrane translocation process. The spectrum of 19F-T6 was not changed even after 46 min (data not shown). The result demonstrates that no interaction occurs between 19F-T6 and HL60 cells. This is also supported by the fact that the spectra of 19F-T6 are not altered after it is added to heparin (Figure 3c), indicating no binding of 19F-T6 to negatively charged GAG on the cell surface.

2.2. Quantitative Analysis of Direct Membrane Translocation

So far, no reports about in-situ quantity of CPPs in cells have been available. Here, by using the integral signal intensities of the real-time 19F NMR difference spectra (Figure 2b), the quantities of four 19F-R8 components, Free, GAG, Membrane, and Cytosol can be evaluated as a function of time. Detailed procedures are described in Appendix A. Figure 6 quantifies how the concentration of each 19F-R8 component varied after the addition to HL60 cells. The amount of free 19F-R8 gradually decreased for the first 5 min. This corresponds to the uptake of free 19F-R8 to HL60 cells via the binding to GAG. At least 65 μM (81%) of 19F-R8 was, however, remaining in a free state after the equilibrium was attained (at 16 min). The amount of 19F-R8 bound to GAG, at first, increased but decreased to less than 5 μM within a short period of 4–6 min. This quick decrease is thought to be due to the transfer of 19F-R8 to the membrane from the cell surface. In fact, the amount of 19F-R8 in the membrane was gradually increased to 9 μM at 6 min, and then slightly decreased. The decrease in 19F-R8 in membrane suggests that the peptide was delivered to cytosol after passing through the membrane. Actually, the transfer of 19F-R8 to cytosol was first observed at around 5 min, followed by the increase up to about 6 μM.
It should be noted that the movement of 19F-R8 from cytosol to the membrane occurs as frequently as the entry into cytosol because the concentrations of 19F-R8 in membrane and in cytosol at the equilibrium state after 16 min are found to be equal within the experimental error. The relatively low concentrations are both reasonable from the fact that cell membranes impose a hydrophobic barrier on highly cationic R8 [49,50].

2.3. 19F-R8 Distribution under Equilibrium

In the previous sections, we succeeded in comprehensive observation and quantitative analysis of the non-endocytic translocation of 19F-R8 to the cell inside. To confirm that 19F-R8 is actually transferred to cytosol across the cell membrane, the final distribution of 19F-R8 was evaluated by cell fractionation after equilibrium was attained in real-time NMR measurements. Membrane solubilization and centrifugation techniques were combined in accordance with Scheme 1. First, we examined how much of 19F-R8 was finally bound to cells. In Figure 7a, the 19F NMR spectra of 19F-R8 in the supernatant I is compared with total 19F-R8 as a control at 4 °C. The 19F NMR signal intensity of the supernatant I corresponds to 19F-R8 that is still in a free (unbound) state under equilibrium. It is found that 77% of 19F-R8 was in a free state. The value is consistent with the result of the real-time in-cell NMR measurement showing about 65 μM (81%) of 19F-R8 is remaining in a free state after the equilibrium is attained (Figure 6). Next, to confirm that 19F-R8 is actually bound to HL60 cell, the cell pellet I was solubilized by lysis buffer containing 1% Triton X-100. After the centrifugation, the supernatant II was subject to 19F NMR measurement at 4 °C. The spectrum is shown in Figure 7b as Lysate, and 13% of the initial 19F-R8 was detected.
It is considered that three components of 19F-R8 are contained in the Lysate. They include 19F-R8 bound to GAG or cell membrane, and 19F-R8 in cytosol. We separated these components as the supernatant III and the pellet III by centrifuging the Lysate at 100,000× g. Supernatant III consists of 19F-R8 in cytosol, and pellet III contains 19F-R8 bound to GAG or cell membrane (referred as Membrane); see Scheme 1. The 19F NMR spectrum of the supernatant III at 4 °C shows that the signal of 19F-R8 is observed in the cytosol fraction; see the red line in Figure 7b. The result is valuable because the 19F-R8 entry into cytosol through HL60 cell membranes is actually demonstrated. This is a contrast to the absence of TFA peak in the Lysate fraction (Figure S3), indicating that the counter TFA ions of 19F-R8 remain outside cells after the real-time in-cell 19F NMR measurement. On the other hand, the 19F-R8 in the membrane fraction is found to be within the experimental error at an equilibrium state. Although undesirable loss of peptide may be induced by the extensive solubilization and centrifugation for cell fractionation, almost no appearance of the membrane fraction is probably due to the signal broadening, as seen in spectra of 19F-R8 bound to GAG or EPC/EPG LUV (Figure 3a,b). It should be noted that the observed chemical shift of NMR signal in this system is too complicated to understand. For example, the cell solubilization exposes 19F-R8 to numerous molecules derived from cells. Also, the cytosol fraction was obtained by lyophilization of 50 mL lysis buffer A. This leads to the increased concentrations of components (Triton X-100, Tris-HCl, EDTA, NaCl in lysis buffer A) in the final sample to be measured. The condition of the solvent such as ionic strength and pH affects the chemical shift of 19F-R8 NMR signal. Thus the integral NMR intensity is useful for the steady state NMR spectra because it is basically proportional to the nuclear concentration [51].
As 19F-R8 is cationic, it is possible that 19F-R8 is finally bound to DNA in the nucleus of HL60 cells. We explored whether 19F-R8 was bound to DNA or cytoskeleton by solubilizing pellet II in accordance with Scheme 1. As shown in Figure 7b, the 19F NMR signal of 19F-R8 in the DNA and cytoskeleton was not yet detectable. Although further investigation is required, this may be due to the fact that the binding of 19F-R8 to cellular component is too tight to be solubilized. In such case, the intensity of the NMR signal is underestimated by the signal broadening, similar to the case of membrane fraction.

3. Discussion

In the present study, we successfully observed the real-time processes of the direct membrane translocation of 19F-R8 into HL60 cells without any perturbation of the system. Based on the results, we can discuss the plausible mechanism as illustrated in Figure 8.
As a first step of the entry into cells, cationic 19F-R8 electrostatically binds to negatively charged GAGs at the cell surface. Consistent with this, the same conclusion has been reached that arginine-rich CPPs such as R8 at first bind to GAGs at the cell surface [20,46]. Considering the fact that the fraction of acidic charged phospholipids in biological plasma membranes is only about 10%–20%, and that the lipids are predominantly distributed to inner leaflet of the membrane [52], it seems that 19F-R8 bound to GAGs remains outside cells. However, contrary to the expectation, quantitative NMR analysis demonstrated the entry of cationic 19F-R8 into hydrophobic cell membrane after binding to GAGs (Figure 2b and Figure 6). One possibility is that the charge neutralization of polyarginine with GAGs would lead to insoluble peptide-GAG complexes [14,17,41], which is likely to be energetically unstable since GAGs are covalently immobilized to membrane protein at the water-abundant cell surface [53,54]. As a result, 19F-R8 bound to GAG is likely to dissociate from GAGs to water or rapidly transfer to cell membrane. Indeed, it was reported that the cationic 19F-R8 bound to the amphipathic sulfate compounds favorably partitions into octanol phase as cell membrane model via hydrophobic interactions [55,56]. In addition, bidentate hydrogen bonding between guanidino group of arginine and lipid phosphate makes the arginine-rich peptides stable in a hydrophobic environment [57,58,59]. Taken together, our results suggest that the charge neutralization of arginine-rich peptides by the presence of negatively charged GAG accelerates the peptide entry into the hydrophobic membrane inside.
Afterwards, 19F-R8 is transferred to the cytosol. In order to enter the inside of cells, 19F-R8 should pass through the hydrophobic cell membrane. Because 19F-R8 is inherently hydrophilic, it is hard to enter the hydrophobic lipid bilayer.
One possibility to compensate this difficulty is to utilize the lipid movement in the vertical direction to the membrane surface. It is expected that the entry of 19F-R8 into the cell is enhanced by synchronization with the vertical fluctuation of the membrane lipid. In fact, such movement, called protrusion, has been observed in the cell-sized lipid bilayer vesicle [60]. In this sense, the lipid protrusion motion is considered as one of the key factors for the direct membrane translocation of CPPs. This is especially the case under physiological conditions at 37 °C. At 4 °C, however, the direct translocation probability of 19F-R8 is low due to impaired membrane fluidity. The protrusion is inhibited at low temperatures even in the fluid phase [60]. Recently, it has been reported that the most plausible mechanism for the direct membrane translocation of arginine-rich peptides is a transient pore formation, in which the peptides induce membrane perturbation so that it can easily pass through the membrane [56,61,62,63,64,65]. The lifetime of the toroidal pore is thought to be short enough to guarantee no cytotoxicity [66,67,68]. The trypan blue staining after the NMR measurement showed that 19F-R8 did not lower cell viability, being consistent with the transient pore formation model.
In conclusion, the present in-cell NMR study is the first report to comprehensively observe and quantitatively analyze the direct translocation processes of cell penetrating 19F-R8 in situ. Based on the results, a new insight into the mechanism for the entry of cationic 19F-R8 into hydrophobic membrane after binding to negatively charged GAGs was obtained. The present study shows a potential for elucidating direct membrane translocation mechanism of CPPs with minimal perturbation.

4. Materials and Methods

4.1. Materials

The 19F-labeled octaarginine (19F-R8: (4CF3-Phe)-RRRRRRRR) was synthesized manually by solid phase synthesis method using Fmoc chemistry. The amino and carboxyl termini of the peptide were acetylated and amidated, respectively. A fragment peptide, called 19F-T6 (TV-(4CF3-Phe)-DSGISEVR), from human lens αA-crystallin [69] was used as a negative control and synthesized by Fmoc solid-phase chemistry using an automated solid-phase synthesizer (PSSM-8; Shimadzu, Kyoto, Japan). The purity of each peptide was confirmed to be > 95% by reversed-phase high-performance liquid chromatography and MALDI-TOF mass spectrometry. Heparin sodium salt (from porcine intestinal mucosa; average molecular weight, 18,000 Da) was purchased from SIGMA (St. Louis, MO, USA). Egg phosphatidylcholine (EPC, > 96% pure) and egg phosphatidylglycerol (EPG, > 95% pure) were obtained from the NOF CORPORATION (Tokyo, Japan). All other reagents were of special grade and used without further purification.

4.2. Cell Culture

A human leukemia cell line HL60 was maintained in RPMI 1640 medium, supplemented with 8% heat-inactivated fetal calf serum (FCS), 100 U/mL penicillin and 100 μg/mL streptomycin in 5% CO2 humidified air at 37 °C.

4.3. Preparation of Large Unilamellar Vesicle (LUV)

EPC/EPG LUV was prepared by using an extrusion method previously reported [70]. Briefly, EPC and EPG were dissolved in chloroform at a molar ratio of PC/PG = 4/1 in a round-bottomed flask and dried with a rotary evaporator to create a thin and homogeneous lipid film. The lipid film was vortexed in Tris-HCl buffer (pH 7.4) containing 15 mM NaCl to obtain vesicle suspension. The resultant suspension was subjected to five cycles of freeze–thawing and was then passed through a Mini-extruder equipped with two stacked 0.1-μm polycarbonate filters (Avanti Polar Lipids, Alabaster, AL, USA). The concentration of phospholipids was determined by the Bartlett method [71].

4.4. Real-Time In-Cell 19F NMR Measurement

One-dimensional in-cell 19F NMR measurements were carried out at 376.2 MHz by using a JEOL ECA400 NMR spectrometer equipped with a superconducting magnet of 9.4 T. A multinuclear probe (JEOL, NM40T10A/AT) for a 10-mm diameter tube was used. Detailed procedures of the measurement are described elsewhere [23]. Briefly, HL60 cells (the final concentration, 1 × 107 cells/mL) were suspended in phosphate-buffered saline (PBS, pH 7.4) at 4 °C and put into a NMR tube. In order to confirm no contribution of energy-dependent endocytosis at 4 °C, the comparative measurement was also performed at 37 °C. To avoid cellular toxicity, the amount of D2O used for the signal lock was decreased to 10%. The sample was gently rotated to prevent the sedimentation of the cells. Field-gradient shimming was applied before the addition of the peptide, to quickly attain the spectral resolution. The measurements started immediately after the thermal equilibrium was attained, 1.5 min after the addition of the 19F-labeled peptides. The final concentrations of 19F-R8 and 19F-T6 were 80 μM and 100 μM, respectively, and these were high enough to observe non-endocytic translocation [7,10,26]. Free induction decays (FIDs) were accumulated at 16 time/2-min intervals. For 19F-R8, the in-cell 19F NMR measurement was repeated three times. The spectra were processed by the JEOL DELTA software. Chemical shift of the 19F NMR signal was obtained by referring to the absorption frequency of the trifluoroacetic acid in the solvent. Cell viability, assessed by the trypan blue staining after the NMR measurement at 4 °C, was 92% ± 1% for 19F-R8 and 94% ± 1% for 19F-T6 with respect to the control value, 94% ± 2%. At 37 °C, the viability was 92% ± 2% and 95% ± 3% in the presence and absence of 19F-R8, respectively.

4.5. Steady State 19F NMR Measurement

The amount of 19F-R8 finally delivered to the cytosol was quantified by 19F NMR under equilibrium in combination with the cell fractionation using membrane solubilization and centrifugation. The cell fractionation procedures are summarized in Scheme 1. After the real-time 19F NMR measurement, 4 mL of the sample were centrifuged at 1500× g for 5 min at 4 °C. Pellet I was washed twice with 4 mL of PBS and centrifuged again. Then the 8 mL of supernatant I was collected and subject to 19F NMR measurement at 4 °C, to quantify free 19F-R8. Next, 4 mL of lysis buffer A (1% Triton X-100, 50 mM Tris-HCl, 50 mM EDTA, 150 mM NaCl, 10% D2O) was added to pellet I, and left for 15 min on ice to complete the cell membrane solubilization. The solution was centrifuged at 15,000× g for 15 min at 4 °C, to separate pellet II and supernatant II. Then, supernatant II was collected and subjected to 19F NMR measurement at 4 °C (called Lysate). After measurement, 50 mL of lysis buffer A was added and centrifuged at 100,000× g for 3 h at 4 °C. Pellet III contains cell membrane and supernatant III corresponded to the cytosol fraction [72]. Pellet III was resuspended in 4 mL of lysis buffer A and subjected to 19F NMR measurement at 4 °C (called Membrane). On the other hand, supernatant III was lyophilized and resuspended in 4 mL of lysis buffer A, and subjected to 19F NMR measurement at 4 °C (Cytosol). Pellet II was incubated in 1 mL of lysis buffer A containing 0.5 M NaCl for 15 min on ice, and added to 3 mL of lysis buffer B (0.05% SDS, 0.5% deoxycholic acid, 50 mM Tris-HCl, 5 mM EDTA, 150 mM NaCl, 10% D2O, pH 7.5). Then the solubilized fractions were subjected to 19F NMR measurement at 4 °C (DNA and cytoskeleton). In each experiment, the FIDs were accumulated 10,000–60,000 times to attain a high signal to noise ratio.

4.6. Isothermal Titration Calorimetry (ITC)

ITC measurements were carried out on an iTC200 system (MicroCal) at 25 °C in 10 mM Tris-HCl buffer at pH 7.4. Peptide solution was placed in the reaction cell, and titrated with aliquots of heparin, or EPC/EPG LUV. The ITC injections were repeated automatically at 25 °C under 1000 rpm stirring. The heats of reaction were corrected for dilution control. Thermodynamic parameters were determined by non-linear least-square fitting of the data using the single site binding model in program Origin for ITC version 7 (MicroCal) with the stoichiometry (n), the enthalpy of the reaction (ΔH°), and the association constant (K) [45,73,74]. The Gibbs free energy ΔG° and entropy ΔS° for binding of R8 to heparin or EPC/EPG LUV were obtained by the following equations:
ΔG° = −RTlnK
and
TΔS° = ΔH° − ΔG°
where T is the absolute temperature.

Supplementary Materials

The following are available online at https://www.mdpi.com/1424-8247/10/2/42/s1, Figure S1: 19F NMR spectrum of 19F-R8 solution, Figure S2: Time course of 19F NMR signal intensity of 19F-R8 after addition to HL60 cells, Figure S3: Final distribution of trifluoroacetate counterions of 19F-R8.

Acknowledgments

This work was partly supported by Grants-in-Aid for Scientific Research 24550035 and 15K05401 from Japan Society for the Promotion of Science, Hyogo Science and Technology Association Research Grant 25073 and performed under the Cooperative Research Program of Institute for Protein Research, Osaka University.

Author Contributions

Y.T-H., Y.T. and E.O. conceived and designed the experiments; Y.T-H., K.A., Y.T., T.K. and E.O. performed the experiments; Y.T-H., K.A., Y.H. and E.O. analyzed the data; Y.T., T.K., H.S. and E.O. contributed reagents/materials/analysis tools; Y.T-H. and E.O. wrote the paper.

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A

Concentration Analysis

Cell peptide concentrations inside and outside were estimated by using the signal intensities of real-time 19F NMR difference spectra in Figure 2b. Figure A1 illustrates how peptide concentrations were determined from the 19F NMR spectra. As compared to the control signal at −62.20 ppm (a), one negative and two positive peaks are found in this case, with respect to the baseline in the difference spectrum (b). The negative peak corresponds to the decreased fraction of free (unbound) peptide because the peak minimum at −62.20 ppm is similar to the control (a). The positive peaks at −62.19 and −62.21 ppm can be assigned to 19F-R8 bound to GAG and cell membrane; see Results for peak assignment.
The concentration of these three components can be evaluated from the signal intensities by integrating the respective peak areas. For example, the fraction of the decrease in free 19F-R8 component, shaded blue area in the spectrum (b), is estimated as 16.3% with respect to the control, 100% (a). Thus, the free component remaining in cell outside is calculated as 83.7%. Similarly, the increase in the fraction bound to GAG (in gray) and membrane (in green) is estimated as 11.4 and 6.6%. Since the total 19F-R8 concentration is 80 μM, the concentrations of free, bound to GAG, and membrane components are calculated to be 67, 9, and 5 μM, respectively.
Pharmaceuticals 10 00042 g009 550
Figure A1. Illustration of the signal intensity estimation in the 19F NMR difference spectrum. The spectrum (a) shows an 19F-R8 signal in PBS (control), and (b) is an example of an NMR difference spectrum obtained by subtracting (a) from the 19F-R8 spectrum 4 min after the peptide was added to cells. The baseline in the difference spectrum is designated by a broken red line. In (b), one negative peak at −62.20 ppm and two positive peaks at −62.19 and −62.21 ppm are found. The negative signal (in blue, shaded) is assigned to 19F-R8 in a free (unbound) state, and positive ones correspond to 19F-R8 bound to GAG (in gray) and cell membrane (in green). The negative peak at −62.20 ppm means the decrease in free peptide. The concentration of these three components can be evaluated from the signal intensities by integrating the respective peak areas (see text).
Figure A1. Illustration of the signal intensity estimation in the 19F NMR difference spectrum. The spectrum (a) shows an 19F-R8 signal in PBS (control), and (b) is an example of an NMR difference spectrum obtained by subtracting (a) from the 19F-R8 spectrum 4 min after the peptide was added to cells. The baseline in the difference spectrum is designated by a broken red line. In (b), one negative peak at −62.20 ppm and two positive peaks at −62.19 and −62.21 ppm are found. The negative signal (in blue, shaded) is assigned to 19F-R8 in a free (unbound) state, and positive ones correspond to 19F-R8 bound to GAG (in gray) and cell membrane (in green). The negative peak at −62.20 ppm means the decrease in free peptide. The concentration of these three components can be evaluated from the signal intensities by integrating the respective peak areas (see text).
Pharmaceuticals 10 00042 g009

References

  1. Trabulo, S.; Cardoso, A.L.; Mano, M.; de Lima, M.C.P. Cell-penetrating peptides-mechanisms of cellular uptake and generation of delivery systems. Pharmaceuticals 2010, 3, 961–993. [Google Scholar] [CrossRef] [PubMed]
  2. Keller, A.A.; Mussbach, F.; Breitling, R.; Hemmerich, P.; Schaefer, B.; Lorkowski, S.; Reissmann, S. Relationships between cargo, cell penetrating peptides and cell type for uptake of non-covalent complexes into live cells. Pharmaceuticals 2013, 6, 184–203. [Google Scholar] [CrossRef] [PubMed]
  3. Howl, J.; Matou-Nasri, S.; West, D.C.; Farquhar, M.; Slaninová, J.; Östenson, C.G.; Zorko, M.; Östlund, P.; Kumar, S.; Langel, Ü.; et al. Bioportide: An emergent concept of bioactive cell-penetrating peptides. Cell. Mol. Life Sci. 2012, 69, 2951–2966. [Google Scholar] [CrossRef] [PubMed]
  4. Liu, B.R.; Lin, M.D.; Chiang, H.J.; Lee, H.; Revon, B. Arginine-rich cell-penetrating peptides deliver gene into living human cells. Gene 2012, 505, 37–45. [Google Scholar] [CrossRef] [PubMed]
  5. Jones, A.T.; Sayers, E.J. Cell entry of cell penetrating peptides and tales of tails wagging dogs. J. Control. Release 2012, 161, 582–591. [Google Scholar] [CrossRef] [PubMed]
  6. Bechara, C.C.; Sagan, S. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett. 2013, 587, 1693–1702. [Google Scholar] [CrossRef] [PubMed]
  7. Kosuge, M.; Takeuchi, T.; Nakase, I.; Jones, A.T.; Futaki, S. Cellular internalization and distribution of arginine-rich peptides as a function of extracellular peptide concentration, serum, and plasma membrane associated proteoglycans. Bioconjug. Chem. 2008, 19, 656–664. [Google Scholar] [CrossRef] [PubMed]
  8. Jiao, C.Y.; Delaroche, D.; Burlina, F.; Alves, I.D.; Chassaing, G.; Sagan, S. Translocation and Endocytosis for Cell-Penetrating Peptide Internalization. J. Biol. Chem. 2009, 284, 33957–33965. [Google Scholar] [CrossRef] [PubMed]
  9. Watkins, C.L.; Schmaljohann, D.; Futaki, S.; Jones, A.T. Low concentration thresholds of plasma membranes for rapid energy-independent translocation of a cell-penetrating peptide. Biochem. J. 2009, 420, 179–189. [Google Scholar] [CrossRef] [PubMed]
  10. Broc, R. The uptake of arginine-rich cell-penetrating peptides: Putting the puzzle together. Bioconjug. Chem. 2014, 25, 863–868. [Google Scholar] [CrossRef] [PubMed]
  11. Ziegler, A. Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans. Adv. Drug Deliv. Rev. 2008, 60, 580–597. [Google Scholar] [CrossRef] [PubMed]
  12. Amand, H.L.; Rydberg, H.A.; Fornander, L.H.; Lincoln, P.; Nordén, B.; Esbjörner, E.K. Cell surface binding and uptake of arginine- and lysine-rich penetratin peptides in absence and presence of proteoglycans. Biochim. Biophys. Acta Biomembr. 2012, 1818, 2669–2678. [Google Scholar] [CrossRef] [PubMed]
  13. Naik, R.J.; Chatterjee, A.; Ganguli, M. Different roles of cell surface and exogenous glycosaminoglycans in controlling gene delivery by arginine-rich peptides with varied distribution of arginines. Biochim. Biophys. Acta Biomembr. 2013, 1828, 1484–1493. [Google Scholar] [CrossRef] [PubMed]
  14. Bechara, C.; Pallerla, M.; Zaltsman, Y.; Burlina, F.; Alves, I.D.; Lequin, O.; Sagan, S. Tryptophan within basic peptide sequences triggers glycosaminoglycan-dependent endocytosis. FASEB J. 2013, 27, 738–749. [Google Scholar] [CrossRef] [PubMed]
  15. Nakase, I.; Niwa, M.; Takeuchi, T.; Sonomura, K.; Kawabata, N.; Koike, Y.; Takehashi, M.; Tanaka, S.; Ueda, K.; Simpson, J.C.; et al. Cellular uptake of arginine-rich peptides: Roles for macropinocytosis and actin rearrangement. Mol. Ther. 2004, 10, 1011–1022. [Google Scholar] [CrossRef] [PubMed]
  16. Mishra, A.; Hwee, G.; Schmidt, N.W.; Sun, V.Z.; Rodriguez, A.R.; Tong, R.; Tang, L.; Lai, G.H.; Cheng, J.; Deming, T.J.; et al. Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. Proc. Natl. Acad. Sci. USA 2011, 108, 16883–16888. [Google Scholar] [CrossRef] [PubMed]
  17. Ziegler, A.; Seelig, J. Contributions of glycosaminoglycan binding and clustering to the biological uptake of the nonamphipathic cell-penetrating peptide WR9. Biochemistry 2011, 50, 4650–4664. [Google Scholar] [CrossRef] [PubMed]
  18. Silhol, M.; Tyagi, M.; Giacca, M.; Lebleu, B.; Vivès, E. Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat. Eur. J. Biochem. 2002, 269, 494–501. [Google Scholar] [CrossRef] [PubMed]
  19. Gump, J.M.; June, R.K.; Dowdy, S.F. Revised role of glycosaminoglycans in TAT protein transduction domain-mediated cellular transduction. J. Biol. Chem. 2010, 285, 1500–1507. [Google Scholar] [CrossRef] [PubMed]
  20. Takechi-Haraya, Y.; Nadai, R.; Kimura, H.; Nishitsuji, K.; Uchimura, K.; Sakai-Kato, K.; Kawakami, K.; Shigenaga, A.; Kawakami, T.; Otaka, A.; et al. Enthalpy-driven interactions with sulfated glycosaminoglycans promote cell membrane penetration of arginine peptides. Biochim. Biophys. Acta Biomembr. 2016, 1858, 1339–1349. [Google Scholar] [CrossRef] [PubMed]
  21. Hirose, H.; Takeuchi, T.; Osakada, H.; Pujals, S.; Katayama, S.; Nakase, I.; Kobayashi, S.; Haraguchi, T.; Futaki, S. Transient focal membrane deformation induced by arginine-rich peptides leads to their direct penetration into cells. Mol. Ther. 2012, 20, 984–993. [Google Scholar] [CrossRef] [PubMed]
  22. Meerovich, I.; Muthukrishnan, N.; Johnson, G.A.; Erazo-Oliveras, A.; Pellois, J.P. Photodamage of lipid bilayers by irradiation of a fluorescently labeled cell-penetrating peptide. Biochim. Biophys. Acta Gen. Subj. 2014, 1840, 507–515. [Google Scholar] [CrossRef] [PubMed]
  23. Okamura, E.; Ninomiya, K.; Futaki, S.; Nagai, Y.; Kimura, T.; Wakai, C.; Matubayasi, N.; Sugiura, Y.; Nakahara, M. Real-time in-cell 19F NMR study on uptake of fluorescent and nonfluorescent 19F-octaarginines into human jurkat cells. Chem. Lett. 2005, 34, 1064–1065. [Google Scholar] [CrossRef]
  24. Szeto, H.H.; Schiller, P.W.; Zhao, K.; Luo, G. Fluorescent dyes alter intracellular targeting and function of cell-penetrating tetrapeptides. FASEB J. 2005, 19, 118–120. [Google Scholar] [CrossRef] [PubMed]
  25. Puckett, C.A.; Barton, J.K. Fluorescein redirects a ruthenium-octaarginine conjugate to the nucleus. J. Am. Chem. Soc. 2009, 131, 8738–8739. [Google Scholar] [CrossRef] [PubMed]
  26. Bertrand, J.R.; Malvy, C.; Auguste, T.; Tóth, G.K.; Kiss-Ivánkovits, O.; Illyés, E.; Hollósi, M.; Bottka, S.; Laczkó, I. Synthesis and studies on cell-penetrating peptides. Bioconjug. Chem. 2009, 20, 1307–1314. [Google Scholar] [CrossRef] [PubMed]
  27. Aubry, S.; Aussedat, B.; Delaroche, D.; Jiao, C.Y.; Bolbach, G.; Lavielle, S.; Chassaing, G.; Sagan, S.; Burlina, F. MALDI-TOF mass spectrometry: A powerful tool to study the internalization of cell-penetrating peptides. Biochim. Biophys. Acta Biomembr. 2010, 1798, 2182–2189. [Google Scholar] [CrossRef] [PubMed]
  28. Lécorché, P.; Walrant, A.; Burlina, F.; Dutot, L.; Sagan, S.; Mallet, J.; Desbat, B.; Chassaing, G.; Alves, I.D.; Lavielle, S. Cellular uptake and biophysical properties of galactose and/or tryptophan containing cell-penetrating peptides. Biochim. Biophys. Acta Biomembr. 2012, 1818, 448–457. [Google Scholar] [CrossRef] [PubMed]
  29. Walrant, A.; Matheron, L.; Cribier, S.; Chaignepain, S.; Jobin, M.L.; Sagan, S.; Alves, I.D. Direct translocation of cell penetrating peptides in liposomes: A combined mass spectrometry quantification and fluorescence detection study. Anal. Biochem. 2013, 438, 1–10. [Google Scholar] [CrossRef] [PubMed]
  30. Aki, K.; Okamura, E. D-β-aspartyl residue exhibiting uncommon high resistance to spontaneous peptide bond cleavage. Sci. Rep. 2016, 6, 21594. [Google Scholar] [CrossRef] [PubMed]
  31. Cobb, S.L.; Murphy, C.D. 19F NMR applications in chemical biology. J. Fluor. Chem. 2009, 130, 132–143. [Google Scholar] [CrossRef]
  32. Kitevski-LeBlanc, J.L.; Prosser, R.S. Current applications of 19F NMR to studies of protein structure and dynamics. Prog. Nucl. Magn. Reson. Spectrosc. 2012, 62, 1–33. [Google Scholar] [CrossRef] [PubMed]
  33. Serber, B.Z.; Corsini, L.; Durst, F.; Serber, Z.; Dötsch, V. In-cell NMR spectroscopy. Methods Enzymol. 2005, 394, 17–41. [Google Scholar] [PubMed]
  34. Suzuki, Y.; Brender, J.J.R.; Hartman, K.; Ramamoorthy, A.; Marsh, E.N.G. Alternative pathways of human islet amyloid polypeptide aggregation distinguished by 19F NMR-detected kinetics of monomer consumption. Biochemistry 2012, 51, 8154–8162. [Google Scholar] [CrossRef] [PubMed]
  35. Shi, P.; Li, D.; Chen, H.; Xiong, Y.; Wang, Y.; Tian, C. In situ 19F NMR studies of an E. coli membrane protein. Protein Sci. 2012, 21, 596–600. [Google Scholar] [CrossRef] [PubMed]
  36. Kitevski-Leblanc, J.L.; Hoang, J.; Thach, W.; Larda, S.T.; Prosser, R.S. 19F NMR studies of a desolvated near-native protein folding intermediate. Biochemistry 2013, 52, 5780–5789. [Google Scholar] [CrossRef] [PubMed]
  37. De la Vega, M.; Marin, M.; Kondo, N.; Miyauchi, K.; Kim, Y.; Epand, R.F.; Emapnd, R.M.; Melikyan, G.B.; de la Vega, M. Inhibition of HIV-1 endocytosis allows lipid mixing at the plasma membrane, but not complete fusion. Retrovirology 2011, 8, 99. [Google Scholar] [CrossRef] [PubMed]
  38. Zeng, J.; Eckenrode, H.M.; Dounce, S.M.; Dai, H. Time-resolved molecular transport across living cell membranes. Biophys. J. 2013, 104, 139–145. [Google Scholar] [CrossRef] [PubMed]
  39. Palm, C.; Jayamanne, M.; Kjellander, M.; Hällbrink, M. Peptide degradation is a critical determinant for cell-penetrating peptide uptake. Biochim. Biophys. Acta Biomembr. 2007, 1768, 1769–1776. [Google Scholar] [CrossRef] [PubMed]
  40. Capila, I.; VanderNoot, V.A.; Mealy, T.R.; Seaton, B.A.; Linhardt, R.J. Interaction of heparin with annexin V. FEBS Lett. 1999, 446, 327–330. [Google Scholar] [CrossRef]
  41. Ziegler, A.; Seelig, J. Interaction of the protein transduction domain of HIV-1 TAT with heparan sulfate: Binding mechanism and thermodynamic parameters. Biophys. J. 2004, 86, 254–263. [Google Scholar] [CrossRef]
  42. Futamura, M.; Dhanasekaran, P.; Handa, T.; Phillips, M.C.; Lund-Katz, S.; Saito, H. Two-step mechanism of binding of apolipoprotein E to heparin: Implications for the kinetics of apolipoprotein E-heparan sulfate proteoglycan complex formation on cell surfaces. J. Biol. Chem. 2005, 280, 5414–5422. [Google Scholar] [CrossRef] [PubMed]
  43. Blaum, B.S.; Deakin, J.A.; Johansson, C.M.; Herbert, A.P.; Barlow, P.N.; Lyon, M.; Uhrín, D. Lysine and arginine side chains in glycosaminoglycan-protein complexes investigated by NMR, cross-linking, and mass spectrometry: A case study of the factor H-heparin interaction. J. Am. Chem. Soc. 2010, 132, 6374–6381. [Google Scholar] [CrossRef] [PubMed]
  44. Noborn, F.; Callaghan, P.O.; Hermansson, E.; Zhang, X.; Ancsin, J.B.; Damas, A.M.; Dacklin, I.; O’Callaghan, P.; Presto, J.; Johansson, J.; et al. Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein. Proc. Natl. Acad. Sci. USA 2011, 108, 5584–5589. [Google Scholar] [CrossRef] [PubMed]
  45. Solomon, J.P.; Bourgault, S.; Powers, E.T.; Kelly, J.W. Heparin binds 8 kDa gelsolin cross-β-sheet oligomers and accelerates amyloidogenesis by hastening fibril extension. Biochemistry 2011, 50, 2486–2498. [Google Scholar] [CrossRef] [PubMed]
  46. Gonçalves, E.; Kitas, E.; Seelig, J. Binding of oligoarginine to membrane lipids and heparan sulfate: Structural and thermodynamic characterization of a cell-penetrating peptide. Biochemistry 2005, 44, 2692–2702. [Google Scholar] [CrossRef] [PubMed]
  47. Okamura, E.; Yoshii, N. Drug binding and mobility relating to the thermal fluctuation in fluid lipid membranes. J. Chem. Phys. 2008, 129, 215102. [Google Scholar] [CrossRef] [PubMed]
  48. Lopes, S.; Simeonova, M.; Gameiro, P.; Rangel, M.; Ivanova, G. Interaction of 5-fluorouracil loaded nanoparticles with 1,2-dimyristoyl-sn-glycero-3-phosphocholine liposomes used as a cellular membrane model. J. Phys. Chem. B 2012, 116, 667–675. [Google Scholar] [CrossRef] [PubMed]
  49. Esbjörner, E.K.; Lincoln, P.; Nordén, B. Counterion-mediated membrane penetration: Cationic cell-penetrating peptides overcome Born energy barrier by ion-pairing with phospholipids. Biochim. Biophys. Acta Biomembr. 2007, 1768, 1550–1558. [Google Scholar] [CrossRef] [PubMed]
  50. Vorobyov, I.; Allen, T.W. On the role of anionic lipids in charged protein interactions with membranes. Biochim. Biophys. Acta Biomembr. 2011, 1808, 1673–1683. [Google Scholar] [CrossRef] [PubMed]
  51. Wider, G.; Dreier, L. Measuring protein concentrations by NMR spectroscopy. J. Am. Chem. Soc. 2006, 128, 2571–2576. [Google Scholar] [CrossRef] [PubMed]
  52. Deleu, M.; Crowet, J.M.; Nasir, M.N.; Lins, L. Complementary biophysical tools to investigate lipid specificity in the interaction between bioactive molecules and the plasma membrane: A review. Biochim. Biophys. Acta Biomembr. 2014, 1838, 3171–3190. [Google Scholar] [CrossRef] [PubMed]
  53. Belting, M. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem. Sci. 2003, 28, 145–151. [Google Scholar] [CrossRef]
  54. Sarrazin, S.; Lamanna, W.C.; Esko, J.D. Heparan sulfate proteoglycans. Cold Spring Harb. Perspect. Biol. 2011, 3, 1–33. [Google Scholar] [CrossRef] [PubMed]
  55. Perret, F.; Nishihara, M.; Takeuchi, T.; Futaki, S.; Lazar, A.N.; Coleman, A.W.; Sakai, N.; Matile, S. Anionic fullerenes, calixarenes, coronenes, and pyrenes as activators of oligo/polyarginines in model membranes and live cells. J. Am. Chem. Soc. 2005, 127, 1114–1115. [Google Scholar] [CrossRef] [PubMed]
  56. Herce, H.D.; Garcia, A.E.; Cardoso, M.C. Fundamental molecular mechanism for the cellular uptake of guanidinium-rich molecules. J. Am. Chem. Soc. 2014, 136, 17459–17467. [Google Scholar] [CrossRef] [PubMed]
  57. Rothbard, J.B.; Jessop, T.C.; Wender, P.A. Adaptive translocation: The role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells. Adv. Drug Deliv. Rev. 2005, 57, 495–504. [Google Scholar] [CrossRef] [PubMed]
  58. Tang, M.; Waring, A.J.; Hong, M. Phosphate-mediated arginine insertion into lipid membranes and pore formation by a cationic membrane peptide from solid-state NMR. J. Am. Chem. Soc. 2007, 129, 11438–11446. [Google Scholar] [CrossRef] [PubMed]
  59. Su, Y.; Waring, A.J.; Ruchala, P.; Hong, M. Membrane-bound dynamic structure of an arginine-rich cell-penetrating peptide, the protein transduction domain of HIV TAT, from solid-state NMR. Biochemistry 2010, 49, 6009–6020. [Google Scholar] [CrossRef] [PubMed]
  60. Takechi, Y.; Saito, H.; Okamura, E. Slow tumbling but large protrusion of phospholipids in the cell sized giant vesicle. Chem. Phys. Lett. 2013, 570, 136–140. [Google Scholar] [CrossRef]
  61. Bobone, S.; Piazzon, A.; Orioni, B.; Pedersen, J.Z.; Nan, Y.H.; Hahm, K.S.; Shin, S.Y.; Stella, L. The thin line between cell-penetrating and antimicrobial peptides: The case of Pep-1 and Pep-1-K. J. Pept. Sci. 2011, 17, 335–341. [Google Scholar] [CrossRef] [PubMed]
  62. Henriques, S.; Melo, M.; Castanho, M. Cell-penetrating peptides and antimicrobial peptides: How different are they? Biochem. J. 2006, 7, 1–7. [Google Scholar] [CrossRef] [PubMed]
  63. Herce, H.D.; Garcia, A.E. Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc. Natl. Acad. Sci. USA 2007, 104, 20805–20810. [Google Scholar] [CrossRef] [PubMed]
  64. Clark, K.S.; Svetlovics, J.; McKeown, A.N.; Huskins, L.; Almeida, P.F. What determines the activity of antimicrobial and cytolytic peptides in model membranes. Biochemistry 2011, 50, 7919–7932. [Google Scholar] [CrossRef] [PubMed]
  65. Last, N.B.; Schlamadinger, D.E.; Miranker, A.D. A common landscape for membrane-active peptides. Protein Sci. 2013, 22, 1–13. [Google Scholar] [CrossRef] [PubMed]
  66. El-Andaloussi, S.; Järver, P.; Johansson, H.J.; Langel, U. Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: A comparative study. Biochem. J. 2007, 407, 285–292. [Google Scholar] [CrossRef] [PubMed]
  67. Sawant, R.R.; Patel, N.R.; Torchilin, V.P. Therapeutic delivery using cell-penetrating peptides. Eur. J. Nanomed. 2013, 5, 141–158. [Google Scholar] [CrossRef]
  68. Jo, J.; Hong, S.; Choi, W.Y.; Lee, D.R. Cell-penetrating peptide (CPP)-conjugated proteins is an efficient tool for manipulation of human mesenchymal stromal cells. Sci. Rep. 2014, 4, 4378. [Google Scholar] [CrossRef] [PubMed]
  69. Aki, K.; Fujii, N. Kinetics of isomerization and inversion of aspartate 58 of αA-crystallin peptide mimics under physiological conditions. PLoS ONE 2013, 8, e58515. [Google Scholar] [CrossRef] [PubMed]
  70. Takechi, Y.; Yoshii, H.; Tanaka, M.; Kawakami, T.; Aimoto, S.; Saito, H. Physicochemical mechanism for the enhanced ability of lipid membrane penetration of polyarginine. Langmuir 2011, 27, 7099–7107. [Google Scholar] [CrossRef] [PubMed]
  71. Bartlett, G.R. Phosphorus assay in column chromatography. J. Biol. Chem. 1959, 234, 466–468. [Google Scholar] [PubMed]
  72. Tohyama, Y.; Yanagi, S.; Sada, K.; Yamamura, H. Translocation of p72syk to the cytoskeleton in thrombin-stimulated platelets. J. Biol. Chem. 1994, 269, 32796–32799. [Google Scholar] [PubMed]
  73. Ziegler, A.; Seelig, J. High affinity of the cell-penetrating peptide HIV-1 Tat-PTD for DNA. Biochemistry 2007, 46, 8138–8145. [Google Scholar] [CrossRef] [PubMed]
  74. Ziegler, A.; Seelig, J. Binding and Clustering of Glycosaminoglycans: A Common Property of Mono- and Multivalent Cell-Penetrating Compounds. Biophys. J. 2008, 94, 2142–2149. [Google Scholar] [CrossRef] [PubMed]
Pharmaceuticals 10 00042 g001 550
Figure 1. Real-time 19F NMR spectra of 19F-labeled R8 (19F-R8) after addition to HL60 cells at (a) 4 and (b) 37 °C. The number attached to each spectrum indicates the passage of time before (0 min) and after the addition to cells (in min unit). The 19F-R8 concentrations and pH values are (a) 80 μM at pH 7.4 and (b) 150 μM at pH 7.3, respectively. At 37 °C (b), a new peak is observed at −61.84 ppm after 10 min, and gradually increased with time. The increase of the peak at −61.84 ppm is coupled with a gradual decrease in the original signal of 19F-R8 at −61.66 ppm. Notice that such kind of signal change is not observed at 4 °C (a).
Figure 1. Real-time 19F NMR spectra of 19F-labeled R8 (19F-R8) after addition to HL60 cells at (a) 4 and (b) 37 °C. The number attached to each spectrum indicates the passage of time before (0 min) and after the addition to cells (in min unit). The 19F-R8 concentrations and pH values are (a) 80 μM at pH 7.4 and (b) 150 μM at pH 7.3, respectively. At 37 °C (b), a new peak is observed at −61.84 ppm after 10 min, and gradually increased with time. The increase of the peak at −61.84 ppm is coupled with a gradual decrease in the original signal of 19F-R8 at −61.66 ppm. Notice that such kind of signal change is not observed at 4 °C (a).
Pharmaceuticals 10 00042 g001
Pharmaceuticals 10 00042 g002 550
Figure 2. Real-time in-cell 19F NMR spectra of 19F-R8 and 19F-T6 at 4 °C. (a) An expansion of the typical 19F NMR spectra of 80 μM 19F-R8 (Figure 1a) in PBS (0 min), and 4, 6, 8, 10, 12, 14 and 16 min after the addition to HL60 cells at 4 °C. The peak top of 19F-R8 in the absence of cells (0 min) is designated by blue dotted line. The red arrow indicates a new component observed at the first step after addition to cells. (b) The difference spectra obtained by subtracting the spectrum of 19F-R8 in PBS (0 min) from the respective spectra of Figure 2a in the presence of HL60 cells. Note that the top spectrum (Free) in Figure 2b is the 19F NMR spectrum of 19F-R8 in PBS (0 min). Four components of 19F-R8 in cell outside (Free), bound to glycosaminoglycan (GAG), bound to cell membrane (Membrane), and in cytosol (Cytosol, *) are designated by the dotted lines in blue, black, green, and red, respectively. For comparison, the real-time in-cell 19F NMR (c) and the difference spectra (d) of 100 μM 19F-T6 in PBS (0 min), and at 4, 8, and 16 min after the addition to HL60 cells are also shown. The upper spectrum in (d) represents 19F-T6 in PBS (0 min).
Figure 2. Real-time in-cell 19F NMR spectra of 19F-R8 and 19F-T6 at 4 °C. (a) An expansion of the typical 19F NMR spectra of 80 μM 19F-R8 (Figure 1a) in PBS (0 min), and 4, 6, 8, 10, 12, 14 and 16 min after the addition to HL60 cells at 4 °C. The peak top of 19F-R8 in the absence of cells (0 min) is designated by blue dotted line. The red arrow indicates a new component observed at the first step after addition to cells. (b) The difference spectra obtained by subtracting the spectrum of 19F-R8 in PBS (0 min) from the respective spectra of Figure 2a in the presence of HL60 cells. Note that the top spectrum (Free) in Figure 2b is the 19F NMR spectrum of 19F-R8 in PBS (0 min). Four components of 19F-R8 in cell outside (Free), bound to glycosaminoglycan (GAG), bound to cell membrane (Membrane), and in cytosol (Cytosol, *) are designated by the dotted lines in blue, black, green, and red, respectively. For comparison, the real-time in-cell 19F NMR (c) and the difference spectra (d) of 100 μM 19F-T6 in PBS (0 min), and at 4, 8, and 16 min after the addition to HL60 cells are also shown. The upper spectrum in (d) represents 19F-T6 in PBS (0 min).
Pharmaceuticals 10 00042 g002
Pharmaceuticals 10 00042 g003 550
Figure 3. 19F NMR spectra of 19F-R8 in the presence of heparin and lipid membrane. 19F NMR spectra of 80 μM 19F-R8 in the presence (red) and absence (black) of (a) 80 μM heparin and (b) a 40-mM EPC/EPG bilayer membrane at 4 °C (pH 7.4). The spectra of 100 μM 19F-T6 in the presence of 200 μM of heparin is also shown in (c) for comparison.
Figure 3. 19F NMR spectra of 19F-R8 in the presence of heparin and lipid membrane. 19F NMR spectra of 80 μM 19F-R8 in the presence (red) and absence (black) of (a) 80 μM heparin and (b) a 40-mM EPC/EPG bilayer membrane at 4 °C (pH 7.4). The spectra of 100 μM 19F-T6 in the presence of 200 μM of heparin is also shown in (c) for comparison.
Pharmaceuticals 10 00042 g003
Pharmaceuticals 10 00042 g004 550
Figure 4. ITC associated with the interaction between R8 and heparin. (a) ITC for heparin (100 μM) injection into R8 (45 μM) at 25 °C. Each peak in heat flow chart corresponds to the injection of 1.0 μL aliquots of heparin. (b) Heat reactions (integrated from the calorimetric trace, and corrected for the dilution control) plotted as a function of heparin/peptide molar ratio. The solid line is the best fit to the experimental data. Buffer: 10 mM Tris-HCl buffer containing 15 mM NaCl at pH 7.4. The calculated parameters are listed in Table 1.
Figure 4. ITC associated with the interaction between R8 and heparin. (a) ITC for heparin (100 μM) injection into R8 (45 μM) at 25 °C. Each peak in heat flow chart corresponds to the injection of 1.0 μL aliquots of heparin. (b) Heat reactions (integrated from the calorimetric trace, and corrected for the dilution control) plotted as a function of heparin/peptide molar ratio. The solid line is the best fit to the experimental data. Buffer: 10 mM Tris-HCl buffer containing 15 mM NaCl at pH 7.4. The calculated parameters are listed in Table 1.
Pharmaceuticals 10 00042 g004
Pharmaceuticals 10 00042 g005 550
Figure 5. ITC associated with the interaction between R8 and lipid membrane. (a) ITC for R8 (51 μM) injection into EPC/EPG LUV (500 μM) at 25 °C. Each peak in heat flow chart corresponds to the injection of 2.0-μL aliquots of R8. (b) Heat reaction (integrated from the calorimetric trace, and corrected for the dilution control) plotted as a function of peptide/lipid molar ratio. The solid line is the best fit to the experimental data. Buffer: 10 mM Tris-HCl buffer containing 15 mM NaCl at pH 7.4. The calculated parameters are listed in Table 1.
Figure 5. ITC associated with the interaction between R8 and lipid membrane. (a) ITC for R8 (51 μM) injection into EPC/EPG LUV (500 μM) at 25 °C. Each peak in heat flow chart corresponds to the injection of 2.0-μL aliquots of R8. (b) Heat reaction (integrated from the calorimetric trace, and corrected for the dilution control) plotted as a function of peptide/lipid molar ratio. The solid line is the best fit to the experimental data. Buffer: 10 mM Tris-HCl buffer containing 15 mM NaCl at pH 7.4. The calculated parameters are listed in Table 1.
Pharmaceuticals 10 00042 g005
Pharmaceuticals 10 00042 g006 550
Figure 6. Real-time changes of 19F-R8 concentrations in HL60 cells. The 19F-R8 concentrations in outside (blue), bound to GAG (black), bound to membrane (green), and in cytosol (red) of HL60 cells at 4 °C are shown as a function of time. Each symbol represents the experimental value from the NMR signal intensity. Solid lines represent a visual guide.
Figure 6. Real-time changes of 19F-R8 concentrations in HL60 cells. The 19F-R8 concentrations in outside (blue), bound to GAG (black), bound to membrane (green), and in cytosol (red) of HL60 cells at 4 °C are shown as a function of time. Each symbol represents the experimental value from the NMR signal intensity. Solid lines represent a visual guide.
Pharmaceuticals 10 00042 g006
Pharmaceuticals 10 00042 sch001 550
Scheme 1. Procedures of cell fractionation after real-time NMR measurement.
Scheme 1. Procedures of cell fractionation after real-time NMR measurement.
Pharmaceuticals 10 00042 sch001
Pharmaceuticals 10 00042 g007 550
Figure 7. Final distribution of 19F-R8 in HL60 cells. (a) 19F NMR spectra of 19F-R8 in PBS (control) and the supernatant I after real-time in-cell 19F NMR measurement at 4 °C. The spectra were obtained at 4 °C, pH 7.4. (b) 19F NMR spectra of 19F-R8 fractions separated by solubilization and centrifugation in accordance with Scheme 1. All spectra were observed at 4 °C and pH 7.5. The signal of cytosol fraction is shifted as a result of the interaction with concentrated lysis buffer components, because supernatant III, containing lysis buffer A, was lyophilized and dissolved in large amount of lysis buffer again.
Figure 7. Final distribution of 19F-R8 in HL60 cells. (a) 19F NMR spectra of 19F-R8 in PBS (control) and the supernatant I after real-time in-cell 19F NMR measurement at 4 °C. The spectra were obtained at 4 °C, pH 7.4. (b) 19F NMR spectra of 19F-R8 fractions separated by solubilization and centrifugation in accordance with Scheme 1. All spectra were observed at 4 °C and pH 7.5. The signal of cytosol fraction is shifted as a result of the interaction with concentrated lysis buffer components, because supernatant III, containing lysis buffer A, was lyophilized and dissolved in large amount of lysis buffer again.
Pharmaceuticals 10 00042 g007
Pharmaceuticals 10 00042 g008 550
Figure 8. A plausible mechanism for non-endocytic, energy-independent translocation of 19F-R8 into cells. The mechanism involves (1) binding of 19F-R8 to GAG at the cell surface, followed by (2) the transfer to the cell membrane and (3) the entry into cytosol.
Figure 8. A plausible mechanism for non-endocytic, energy-independent translocation of 19F-R8 into cells. The mechanism involves (1) binding of 19F-R8 to GAG at the cell surface, followed by (2) the transfer to the cell membrane and (3) the entry into cytosol.
Pharmaceuticals 10 00042 g008
Table
Table 1. Thermodynamic parameters for the interaction of R8 with heparin or egg phosphatidylcholine (EPC)/egg phosphatidylglycerol (EPG) large unilamellar vesicles (LUVs) obtained from isothermal titration calorimetry (ITC).
Table 1. Thermodynamic parameters for the interaction of R8 with heparin or egg phosphatidylcholine (EPC)/egg phosphatidylglycerol (EPG) large unilamellar vesicles (LUVs) obtained from isothermal titration calorimetry (ITC).
Binding Stoichiometry (n)K (M−1)ΔG° (kcal/mol)ΔH° (kcal/mol)TΔS° (kcal/mol)
HeparinR8/heparin = 11 ± 1.1(1.3 ± 0.22) × 108−10.9 ± 0.10−9.6 ± 0.531.3 ± 0.54
EPC/EPG LUVlipid/R8 = 100 ± 10(1.5 ± 0.25) × 106−8.4 ± 0.10−6.3 ± 0.102.1 ± 0.10
For original ITC data, see Figure 4 and Figure 5.

Share and Cite

MDPI and ACS Style

Takechi-Haraya, Y.; Aki, K.; Tohyama, Y.; Harano, Y.; Kawakami, T.; Saito, H.; Okamura, E. Glycosaminoglycan Binding and Non-Endocytic Membrane Translocation of Cell-Permeable Octaarginine Monitored by Real-Time In-Cell NMR Spectroscopy. Pharmaceuticals 2017, 10, 42. https://doi.org/10.3390/ph10020042

AMA Style

Takechi-Haraya Y, Aki K, Tohyama Y, Harano Y, Kawakami T, Saito H, Okamura E. Glycosaminoglycan Binding and Non-Endocytic Membrane Translocation of Cell-Permeable Octaarginine Monitored by Real-Time In-Cell NMR Spectroscopy. Pharmaceuticals. 2017; 10(2):42. https://doi.org/10.3390/ph10020042

Chicago/Turabian Style

Takechi-Haraya, Yuki, Kenzo Aki, Yumi Tohyama, Yuichi Harano, Toru Kawakami, Hiroyuki Saito, and Emiko Okamura. 2017. "Glycosaminoglycan Binding and Non-Endocytic Membrane Translocation of Cell-Permeable Octaarginine Monitored by Real-Time In-Cell NMR Spectroscopy" Pharmaceuticals 10, no. 2: 42. https://doi.org/10.3390/ph10020042

APA Style

Takechi-Haraya, Y., Aki, K., Tohyama, Y., Harano, Y., Kawakami, T., Saito, H., & Okamura, E. (2017). Glycosaminoglycan Binding and Non-Endocytic Membrane Translocation of Cell-Permeable Octaarginine Monitored by Real-Time In-Cell NMR Spectroscopy. Pharmaceuticals, 10(2), 42. https://doi.org/10.3390/ph10020042

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop